Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 321

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 321
---
 a capital contribution in cash to the Company and, in exchange for such capital contribution, subscribing for and being issued by the Company on the Closing Date, free and clear of all liens, an aggregate number of Company Shares (at a price per Company Share of $10.00) resulting from dividing the amount of such capital contribution in cash by ten (10) (rounded down to the nearest whole Company Share); and/or (ii) causing SPAC Shareholders who have elected to exercise their SPAC Shareholder Redemption Rights to (A) irrevocably reverse their exercise of the SPAC Shareholder Redemption Rights and not redeem (“Redemption Reversals”), and, (B) transfer all their respective rights, title and interest in all SPAC Ordinary Shares subject to Redemption Reversals, directly or indirectly, to Theo. Any Public Shares purchased pursuant to the Backstop Agreement will (i) be purchased at a price no higher than the price offered through the SPAC redemption process, (ii) not be voted in favor of the business combination transaction and (iii) not have redemption rights, or such rights would be waived. Any issuance of Company Shares to Theo in connection with the funding of the Backstop Amount will have a dilutive effect on current SPAC Shareholders. See section entitled “ Questions and Answers About the Business Combination and the Special Meeting — What equity stake will our current shareholders and shareholders of the Target hold in OmnigenicsAI immediately after consummation of the Business Combination?”, which includes a table reflecting the post -BusinessCombination ownership of the Company, inclusive of the potential issuance pursuant to the Backstop Agreement. The parties to the Backstop Agreement will benefit from the backstop transactions and the consummation of the Business Combination, which benefits are different from, or in addition to, those available to SPAC Shareholders and warrant holders generally. See the section entitled “ Summary of the Proxy Statement / Prospectus — Interests of Certain Persons in the Business Combination.” Voting and Support Agreement Concurrently with the execution of the Business Combination Agreement, SPAC, the Sponsor, the Company and the Parent have each executed and delivered to the Company and SPAC the Support Agreement, pursuant to which, among other things, the Sponsor agreed to vote any of the Sponsor Current Shares (as defined in the Support Agreement) and any SPAC Ordinary Shares held by the Sponsor in favor of the Business Combination. The Sponsor received no consideration (in cash or other form of value) in exchange for entering into the Voting and Support Agreement